Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Example EvidenceVariable: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

Generated Narrative: EvidenceVariable 236950

version: 72; Last updated: 2025-03-20 18:40:09+0000

Profile: GroupAssignment

RelatesTo

  • type: part-of
  • targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

url: https://fevir.net/resources/EvidenceVariable/236950

identifier: FEvIR Object Identifier/https://fevir.net/FOI/236950, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-group-assignment-85394-85798

name: GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA

title: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

Definitions

-Concept
*Defined in handling and category elements

handling: dichotomous variable

category

name: SGLT2 inhibitors

value: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors

category

name: GLP-1 RA

value: Glucagon-Like Peptide-1 (GLP-1) receptor agonists